Crinetics Pharmaceuticals has received European Commission approval for PALSONIFY® (paltusotine), marking it as the first once-daily, oral therapy for treating acromegaly. This approval stems from robust data derived from the pivotal PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, which demonstrated PALSONIFY’s efficacy in both treatment-naïve and previously treated patients. The trials highlighted the drug’s ability to achieve rapid biochemical control and sustained efficacy, as evidenced by significant reductions in IGF-1 levels—the primary biomarker for managing acromegaly—and associated symptoms such as headaches and joint pain.

The clinical significance of PALSONIFY lies in its potential to establish a new standard of care for acromegaly patients. The treatment not only showed a favorable safety profile, with no serious adverse events reported, but also achieved substantial symptom relief as measured by the Acromegaly Symptom Diary (ASD). This validated patient-reported outcome tool underscores the real-world impact of PALSONIFY on patients’ quality of life, emphasizing its therapeutic potential beyond traditional injectable therapies.

The approval of PALSONIFY in the EU represents a crucial advancement in the treatment landscape for acromegaly, with implications for future research and drug development. It may shift current paradigms by encouraging a move toward oral therapies in endocrine disorders, potentially expediting timelines for similar drug candidates targeting G-protein coupled receptors (GPCRs). As Crinetics plans initial commercialization efforts in Germany and Austria, the success of PALSONIFY could catalyze further exploration into oral formulations for other endocrine conditions, thereby enhancing patient adherence and outcomes in the long term.

Source: globenewswire.com